Lupus News and Research

Latest Lupus News and Research

IQWiG examines added benefit of belimumab for patients with systemic lupus erythematosus

Belimumab has been approved since July 2011 as an add-on therapy for adult patients with the autoimmune disease systemic lupus erythematosus (SLE). Products (AMNOG).

30 Aug 2012

New silicon chips help identify patients with lupus

Researchers at the Stanford University School of Medicine and Intel Corp. have collaborated to synthesize and study a grid-like array of short pieces of a disease-associated protein on silicon chips normally used in computer microprocessors.

21 Aug 2012

Kineta receives regulatory clearance to commence ShK-186 Phase I trial in autoimmune disease

Seattle-based biotech company Kineta, Inc. announced today it has received regulatory clearance in the Netherlands to initiate a first-in-human trial of ShK-186, an autoimmune drug candidate that specifically inhibits the Kv1.3 potassium ion channel.

21 Aug 2012

House Bill 6218 would create interdepartmental autoimmune disease coordinating committee

Autoimmune disease patients received a win recently when U.S. Rep. Ann Marie Buerkle (R-NY) introduced House Bill 6218 to Congress. The bill would create an interdepartmental autoimmune disease coordinating committee.

21 Aug 2012

Happtique introduces mRx solution for electronically prescribing medical apps

Happtique, a mobile health application store and total app management solution, today announced the commencement of its pilot program of mRx, Happtique's patent-pending solution that enables physicians and other health practitioners to electronically prescribe medical, health, and fitness apps to their patients.

20 Aug 2012

Link between chronic exposure to staph bacteria and risk of lupus

Chronic exposure to even small amounts of staph bacteria could be a risk factor for the chronic inflammatory disease lupus, Mayo Clinic research shows. Staph, short for Staphylococcus aureus, is a germ commonly found on the skin or in the nose, sometimes causing infections.

9 Aug 2012

Active Biotech, Teva to commence third Phase III study of laquinimod for RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech provided today an update on the clinical development program of once-daily oral laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS).

9 Aug 2012

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

Hydroxychloroquine fails to modify HIV in patients not taking ART

The use of hydroxychloroquine does not reduce CD8 cell activation in HIV-infected patients not taking antiretroviral therapy, research shows.

30 Jul 2012

Questcor second quarter net sales increase to $112.5 million

Questcor Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2012.

24 Jul 2012

PAMAM G-3 actually prevents activation of the process that leads to thrombosis

A compound that mops up debris of damaged cells from the bloodstream may be the first in a new class of drugs designed to address one of medicine's most difficult challenges -- stopping the formation of blood clots without triggering equally threatening bleeding.

24 Jul 2012

Anthera announces final set of clinical data from blisibimod Phase 2b study on SLE

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced the final set of clinical data from the Phase 2b PEARL-SC study in patients with systemic lupus erythematosus.

17 Jul 2012

U.S. News & World Report names Hospital for Special Surgery among 2012 America's Best Hospitals

For the third consecutive year, U.S. News & World Report named Hospital for Special Surgery the top hospital in the country for orthopedics in its 2012 "America's Best Hospitals" survey. Once again, the hospital ranked as a leader in rheumatology at number three in the nation. In addition, neurology was ranked at No. 10.

17 Jul 2012

Researchers describe inflammatory mechanism of sunburn

The biological mechanism of sunburn - the reddish, painful, protective immune response from ultraviolet (UV) radiation - is a consequence of RNA damage to skin cells, report researchers at the University of California, San Diego School of Medicine and elsewhere in the July 8, 2012 Advance Online Publication of Nature Medicine.

9 Jul 2012

Targeting double-stranded RNA dependent protein kinase could treat inflammation

Researchers at The Feinstein Institute for Medical Research have discovered that inflammation could be treated by targeting a molecule called the double-stranded RNA dependent protein kinase (PKR). These findings are published in the July issue of Nature.

9 Jul 2012

Study illuminates key step in the journey of inflammation-producing immune cells

Like detectives seeking footprints and other clues on a television "whodunit," science can also benefit from analyzing the tracks of important players in the body's molecular landscape. Klaus Ley, M.D., a scientist at the La Jolla Institute for Allergy & Immunology, has done just that and illuminated a key step in the journey of inflammation-producing immune cells.

2 Jul 2012

Novo Nordisk, BRI collaborate to speed-up translational research of autoimmune diseases

Benaroya Research Institute at Virginia Mason (BRI), a non-profit biomedical research institute in Seattle, Wash., and Novo Nordisk, a global health care company headquartered in Denmark, today announced a three-year collaborative agreement to potentially speed-up translational research of the diagnosis and treatment of rheumatoid arthritis, inflammatory bowel disease and lupus.

29 Jun 2012

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Infinity Pharmaceuticals, Inc. today reported preclinical data for IPI-145, the company's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data demonstrate potent PI3K-delta and -gamma inhibition in biochemical, cellular and whole blood assays and activity in multiple preclinical models of inflammatory disease, including rheumatoid arthritis and asthma.

28 Jun 2012

Anthera announces results from blisibimod Phase 2b study on SLE

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced results from the Phase 2b PEARL-SC clinical study in patients with systemic lupus erythematosus.

28 Jun 2012

AARDA to host forum related to autoimmune diseases on Aug. 4

The American Autoimmune Related Diseases Association (AARDA) is hosting a "What Every American Needs to Know About Autoimmune Disease" forum on Saturday, August 4th , 2012.

27 Jun 2012